Cardiovascular Systems Revenue and Competitors
Estimated Revenue & Valuation
- Cardiovascular Systems's estimated annual revenue is currently $256.8M per year.
- Cardiovascular Systems received $40.0M in venture funding in April 2017.
- Cardiovascular Systems's estimated revenue per employee is $266,667
- Cardiovascular Systems's total funding is $98M.
- Cardiovascular Systems's current valuation is $777.8M. (January 2022)
- Cardiovascular Systems has 963 Employees.
- Cardiovascular Systems grew their employee count by -4% last year.
Cardiovascular Systems Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Cardiovascular Systems?
Cardiovascular Systems, Inc. (CSI) is devoted to developing and commercializing innovative solutions for treating peripheral and coronary vascular disease. Our primary focus is helping physicians conquer even the most difficult disease states, including arterial calcium, given the complications it presents for the millions who suffer from peripheral arterial disease (PAD) and coronary artery disease (CAD). CSI is committed to clinical rigor, constant innovation, and a defining drive to set the standard in safe, effective, economical medical devices that improve patient outcomes.keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals
Number of Employees
Employee Growth %
Cardiovascular Systems News
Do Analysts Agree Thursday on Cardiovascular Systems Inc (CSII) Stock's Target Price? Thursday, April 21, 2022 12:04 PM | InvestorsObserver Analysts.
--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) plans to announce its operating results for the quarter ended March 31,...
Cardiovascular Systems reported a loss of 23 cents per share for second-quarter fiscal 2022, wider than the Zacks Consensus Estimate of a...
Cardiovascular Systems (Nasdaq: CSII) announced today that it is expanding its product portfolio through new partnerships with OrbusNeich and Integer. The OrbusNeich partnership makes St. Paul, Minn.–based CSI the exclusive U.S. distributor of Hong Kong–based OrbusNeich‘s balloon products. The ...
Bolstered by a 15 percent increase in revenues from year-ago levels — all but a relative sliver coming from reorders — Cardiovascular Systems Inc. (NSDQ:CSII) narrowed its net loss by $1.2 million, to $4.4 million, during the final three months of its 2010 fiscal year. The St. Paul, Minn.-based ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Cardiovascular Systems Funding
|2006-08-01||$25.0M||Undisclosed||Easton Capital Group, Maverick Capital Funds||Article|
|2006-09-20||$25.0M||A||Easton Capital Partners L.P||Article|
|2010-04-21||$29.0M||Undisclosed||Silicon Valley Bank||Article|
|2017-04-05||$40.0M||Undisclosed||Silicon Valley Bank||Article|